Stockreport

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 [Seeking Alpha]

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming for a functional HBV cure superior to downstream competitors. Recent $75M capital raise extends DTIL's c [Read more]